A Randomised, placebo-controlled clinical trial of CTX cell therapy in disabled stroke patients

Trial Profile

A Randomised, placebo-controlled clinical trial of CTX cell therapy in disabled stroke patients

Planning
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs ReN 001 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Nov 2017 New trial record
    • 31 Oct 2017 Company plans to submit an Investigational New Drug application to the FDA shortly and commence this trial in early 2018 with data expected to be available earlier, in the second half of 2019, according to a ReNeuron media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top